Foxiling (butaselen) / Shanghai Yuanxi Pharma - LARVOL DELTA

The novel thioredoxin reductase inhibitor butaselen suppresses lung cancer by inducing oxidative stress. (PubMed, Redox Rep) - "The TrxR/Trx inhibitor butaselen suppresses lung cancer by triggering ROS-induced apoptosis. This study provides a novel and effective regimen for treating lung cancer."

Journal • Lung Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • CDKN1A • DNMT1 • HBP1 • HOXA9

Novel Thioredoxin reductase 1 inhibitor BS1801 relieves treatment resistance and triggers endoplasmic reticulum stress by elevating reactive oxygen species in glioma. (PubMed, Redox Biol) - "Glioma patients will inevitably develop resistance to temozolomide (TMZ) leading to tumor recurrence. In summary, BS1801 treatment can elevate ROS levels, induce glioblastoma cell apoptosis and activate ER stress, thereby relieving TMZ resistance. BS1801 exhibits potent glioma inhibitory effects and potential clinical application."

Journal • Brain Cancer • Glioblastoma • Glioma • Metabolic Disorders • Oncology • Solid Tumor

Orphan Designation: treatment of cholangiocarcinoma (FDA) - Date Designated: 12/05/2024

Orphan drug • Cholangiocarcinoma